Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: TSX
Sector: Pharmaceuticals
Epic: TSX:SBS
News: Latest news
Web Site: SemBioSys Genetics
Other Articles:

RSS - Subscribe to the News Today on Proactive UK ▼

Friday July 03, 10:01Commercial property: The contrarian view

The global recession has hit commercial real estate companies hard, with capital values falling 43.6% from their peak in June 2007.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Friday July 03, 05:05White Canyon Uranium CEO to progress production at Daneros Uranium Mine in 2009

The company has a new Managing Director and CEO - Peter Batten - as of this week. The Daneros Mine has recently received its Permit to Mine in Utah - with production expected in 2009.

FULL ARTICLE ►
SemBioSys Genetics

SemBioSys Genetics

SemBioSys Genetics Inc. is a plant biotechnology company with a technology that enables production of high-value pharmaceutical and non-pharmaceutical products in an affordable and sustainable manner.
Tuesday, January 06, 2009

SemBioSys gets US$2.5 mln from option agreement with MannKind for plant-produced insulin

Biotechnology group SemBioSys Genetics Inc said it has received US$ 2.5 million from MannKind Corp as payment for the option agreement and issuance of 2.4 million SemBioSys unit, as announced on December 24, 2008.


The transaction gives MannKind the option to the license rights to SemBioSys' proprietary plant-produced recombinant human insulin for use primarily in MannKind's ultra-rapid acting insulin, AFRESA.


The units were issued at a price US$0.83 and consist of one common share of SemBioSys and one-tenth of one common share purchase warrant of SemBioSys. Each whole warrant entitles MannKind to purchase one additional common share of SemBioSys at an exercise price of CDN$6.00 for a period of 36 months from the effective date of the option. The option period for the license rights ends on March 31, 2009.


Calgary, Alberta-based SemBioSys develops protein-based pharmaceuticals using its proprietary protein production technology. This technology enables the production of therapeutic proteins in plant seeds by genetically enhancing the safflower plant. SemBioSys' lead pharmaceutical candidates are recombinant human insulin.

AddThis Feed Button
Register here to be notified of future SemBioSys Genetics articles.

Investors interested in SemBioSys Genetics recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.